- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.09. | Y-mAbs Therapeutics, Inc. - 15-12G, Securities registration termination | 2 | SEC Filings | ||
| 16.09. | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.09. | NSE - Y-mAbs Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| 08.08. | Y-mAbs Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Y-MABS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.08. | Y-mAbs Therapeutics GAAP EPS of -$0.07 beats by $0.19, revenue of $19.53M beats by $1.13M | 1 | Seeking Alpha | ||
| 08.08. | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | 281 | GlobeNewswire (Europe) | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
| 07.08. | A Look Ahead: Y-mAbs Therapeutics' Earnings Forecast | 1 | Benzinga.com | ||
| 07.08. | Y-mAbs Therapeutics, Inc.: Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 | 2 | GlobeNewswire (USA) | ||
| 05.08. | Y-mAbs Therapeutics stock downgraded to Hold by Truist after SERB acquisition | 2 | Investing.com | ||
| 05.08. | Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition | 2 | Investing.com | ||
| 05.08. | Y-mAbs signs off on $412M sale to SERB Pharmaceuticals, sending shares up 100% | 2 | FiercePharma | ||
| 05.08. | SERB To Acquire Y-mAbs | 2 | RTTNews | ||
| 05.08. | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | SERB Pharmaceuticals to acquire Y-mAbs Therapeutics for $412M | 1 | Seeking Alpha | ||
| 15.07. | Y-mAbs Therapeutics: Aktionäre stimmen auf Hauptversammlung allen Vorschlägen zu | 2 | Investing.com Deutsch | ||
| 15.07. | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.05. | Clear Street erhöht Kursziel für Y-mAbs-Aktie auf 17 US-Dollar, Aktien steigen | 1 | Investing.com Deutsch | ||
| 28.05. | Clear Street raises Y-mAbs stock target to $17, shares rise | 1 | Investing.com | ||
| 28.05. | Y-mAbs Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Y-mAbs Therapeutics, Inc.: Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline | 3 | GlobeNewswire (USA) |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,65 | +0,50 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| CUREVAC | 4,572 | -1,08 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 23,620 | -1,11 % | Watch Cigna, Moderna, Reddit, and More | ||
| NOVAVAX | 7,338 | +0,60 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,920 | -2,34 % | Heidelberg Pharma erhält Rückenwind von der FDA | Die US-Zulassungsbehörde macht Tempo. Heidelberg Pharma (ISIN DE000A11QVV0) hat für seinen Wirkstoffkandidaten HDP-101 den Fast-Track-Status von der FDA erhalten. Das ist mehr als nur ein bürokratischer... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 55,50 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,040 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,110 | +0,09 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| EDITAS MEDICINE | 2,725 | +1,49 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| DYNAVAX | 8,984 | +0,97 % | Dynavax Technologies: Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial | Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile
Newly presented data outline robust... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 21,140 | +1,54 % | A Peek at Sarepta Therapeutics' Future Earnings | ||
| BIOMARIN PHARMACEUTICAL | 44,770 | -3,58 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen |
Y-MABS THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,610 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu Y-MABS THERAPEUTICS INC finden Sie auf Wallstreet Online.